HISTOGEN INC - HSTO STOCK NEWS

Paracrine, Inc. has appointed David Crean, Ph.D., as an independent Director, enhancing its board with his extensive healthcare experience. Crean's role is crucial as Paracrine develops innovative cell therapies targeting the $21 billion advanced wound care market. He expressed enthusiasm for advancing the company’s clinical and commercialization strategy, particularly in treating diabetic foot ulcers, where their therapy has shown promising results with twice the wound closure rate in half the time. Paracrine is focused on addressing chronic illnesses through its unique cell therapy platform.

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, will release its financial results for Q1 2022 after market close on May 12, 2022. The company focuses on restorative therapeutics and caspase inhibitors for infectious and inflammatory diseases. Key product candidates include HST-003 for joint cartilage repair and HST-004 for spinal disc repair. Notably, emricasan is being developed for COVID-19 treatment in partnership with Amerimmune and is under evaluation for other diseases like MRSA.

Histogen Inc. (NASDAQ: HSTO) announced the closing of a private placement involving 2,500 shares of Series A and Series B redeemable convertible preferred stock, priced at $952.38 each, raising approximately $4.75 million. The preferred stocks are convertible into common shares at an initial price of $1.00, contingent upon stockholder approval for a reverse stock split. H.C. Wainwright & Co. acted as the exclusive placement agent. Proceeds will be used for working capital and corporate purposes, with an SEC registration statement to be filed by July 20, 2022.

Histogen Inc. (NASDAQ: HSTO) announced a securities purchase agreement with institutional investors for 2,500 shares of Series A and 2,500 shares of Series B redeemable convertible preferred stock at a purchase price of $952.38 each, generating approximately $4.75 million in net proceeds. Each preferred share converts to common stock at an initial price of $1.00, subject to stockholder approval for a reverse stock split. The offering is expected to close around March 25, 2022. The proceeds will be used for working capital and general corporate purposes.

Histogen Inc. (NASDAQ: HSTO) announced its fourth quarter and full-year financial results for 2021. The company is focused on cartilage regeneration therapies, with HST-003 in Phase 1/2 study expected to yield top-line results in H1 2023. Revenue for Q4 2021 was $0, a decrease from $0.5 million in 2020, attributed to fulfilled supply orders to Allergan. R&D expenses increased to $1.6 million. The company has $18.7 million in cash, projected to cover operations into mid-2023. A dispute with Amerimmune regarding emricasan for COVID-19 may lead to independent development.

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, will release its financial results for Q4 and the year ending December 31, 2021, on March 10, 2022, after market close. The company focuses on developing first-in-class restorative therapeutics, utilizing innovative technology that includes cell-conditioned media and extracellular matrix materials from hypoxia-induced multipotent cells. Histogen aims to provide solutions for various therapeutic applications, including joint cartilage regeneration and soft tissue repair.

Histogen Inc. (NASDAQ: HSTO) announced the successful closing of a private placement, issuing 8,235,297 shares and warrants at $0.425 each, yielding approximately $3.5 million in gross proceeds. The funds will be utilized for working capital and general corporate purposes. The warrants are exercisable after six months for five and a half years. The offering was executed without public registration, necessitating a future registration statement with the SEC. This strategic capital raise aims to bolster Histogen's focus on regenerative therapeutics.

Histogen Inc. (NASDAQ: HSTO) announced a private placement to issue 8,235,297 shares of common stock and warrants for expected gross proceeds of approximately $3.5 million. The shares will be sold at a price of $0.425 each, with warrants exercisable for up to five and a half years post-issuance. The funding supports working capital and corporate purposes, with closing anticipated around December 20, 2021. Additionally, Histogen plans to file a registration statement with the SEC for resale of the shares within 15 days, which must be declared effective within 75 days.